Glibenclamide
Brand: Glynase (US) / Daonil (IN) / Glybenta (BD)
Antidiabetic
Sulfonylurea (insulin secretagogue)
Pharmacokinetics
| Half-life | 10 hours |
| Tmax | 4 h |
| Bioavailability | 90 % (approx) |
| Protein Binding | 99 % |
| Volume of Distribution | 0.2 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | High hypoglycemia risk especially in elderly and CKD → avoid if possible. |
⚠️ Safety & Warnings
Severity: Severe
Adverse Effects:
Severe hypoglycemia, weight gain, dizziness
Contraindications:
Type 1 DM, DKA, elderly, CKD
Precautions:
Avoid in elderly/renal impairment; prefer safer alternatives